ArticleCureus2025
Optimizing Hepatobiliary Lesion Assessment: The Role of Rapid On-Site Evaluation and Toluidine Blue Staining in Cytology.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFine-needle aspiration cytology (FNAC) is a broadly accepted method for diagnostic evaluation of pathological lesions. Rapid On-Site Evaluation (ROSE) of smears has been proven to improve the diagnostic yield of image-guided FNACs significantly. There are limited studies on the use of ROSE for image-guided FNACs from biliary tract lesions in our country.
objectiveTo determine the utility and efficacy of ROSE on FNAC from neoplastic and non-neoplastic lesions of the hepatobiliary tract. METHODOLOGY: A prospective study was conducted wherein ROSE was performed for FNACs from 50 patients with hepatobiliary tract lesions. Samples were stained with toluidine blue to check adequacy based on the proposed adequacy criteria. Cytological slides were later analyzed after staining with May-Grünwald Giemsa and Papanicolaou stains. Results were compared with those obtained from FNAC without on-site evaluation done retrospectively.
resultsFrom 2007 to 2016, 47 out of 330 image-guided FNACs (without ROSE) from hepatobiliary lesions were non-diagnostic. In contrast, during our study (2021-2022), only 2 out of 50 image-guided FNACs (with ROSE) were non-diagnostic. The diagnostic yield of FNAC increased from 85.76% to 96% (
conclusionsROSE with toluidine blue staining significantly increases the diagnostic yield of hepatobiliary FNACs and eliminates the need for repeat procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.